SIRT6 and myeloid sarcoma: In order to investigate the effect of Sirt6 inhibition during the inflammatory phase and to provide the experimental basis for a possible, new therapeutic approach in MS, 1 was administered according to both a “preventive” (i.e., administration before disease onset) and a “therapeutic” (i.e., administration after disease onset) protocol.